Approved via the EU Decentralised Procedure (DCP) led by the Netherlands with Germany as reference member state, filed in 2021, Guangzhou Hairui’s Parecoxib Sodium for Injection has recently obtained marketing authorization in Germany. Another key EU market access achieved. Every step forward reflects solid strength.
Every step from signing to approval and launch is solid, strengthening our global progress. From signing to approval and official launch, every step is a testament to our strength. Safer, faster-acting, and more flexible in administration, Parecoxib Sodium from Yangtze River Pharmaceutical Group is providing global postoperative patients with an accessible, reliable, and trusted new option for analgesia.